Evolving Your Biopharma ESG Reporting Strategy & Preparing for Regulatory ESG Disclosures
Time: 1:35 pm
day: Pre-Conference Day
Details:
Deep dive into how life sciences organizations are preparing to enhance their ESG and sustainability reporting in a rapidly evolving regulatory landscape. Learn how your peers approach their double materiality assessments, connect the dots between different disclosure frameworks, and evolve ESG operating models to enhance crossfunctional collaboration and ensure regulatory compliance.
Content this session will cover:
- Overview of key ESG regulations for large biopharma companies in the US (CSRD, SEC climate disclosure rule, California Climate Bills, CS3D) and their links to other disclosure frameworks
- Preparing for CSRD reporting: Conducting a double materiality assessment (DMA) and identifying relevant disclosures, ensuring data integrity and the role of technology, developing an auditable report
- Integrating the DMA with existing enterprise risk management processes
- Considering CS3D in your preparations for CSRD
- Enhancing your ESG operating model and cross-functional collaboration: Engaging key stakeholders (e.g. subject matter experts, legal, finance, audit, communications) to operationalize regulatory ESG disclosure readiness
